Flood of drugs, little oversight
Chicago Tribune, March 3, 2008
A congressional committee is asking whether the FDA's recent lapse in allowing a plant it never inspected to export to the U.S. is part of a larger problem of poor oversight and a shortage of resources at the agency. Although FDA officials insist the agency inspects every foreign plant sending medical products to the U.S., the agency's own data make it appear unlikely. An FDA-appointed commission that studied the agency's inspection record found the FDA is short of financial resources, has cut personnel, has rickety data management systems and is struggling to meet its oversight obligations.
- CFO Exchange: Smartphones Poised to Disrupt Healthcare, Says Topol
- How Digital Strategy Shapes Patient Engagement at Boston Children's Hospital
- Half of All Primary Care, Internal Medicine Jobs Unfilled in 2013
- CNO on Hospital Redesign: 'You Can't Over-Communicate'
- Consumerism Drives Healthcare Branding, Rebranding Efforts
- Carondelet to Pay $35M to Settle Fraud Allegations
- PA Ranks See 'Phenomenal Growth,' Lack of Diversity
- Some Cancer Hospitals' Quality Data Will Soon Be Public
- 3 Traits Personality Assessments Can't Reveal
- CA Powers Up $80M HIE to 'Create Value in the Data'